HUTCHMED DRC
NASDAQ: HCM (HUTCHMED (China) Limited)
Kemas kini terakhir: 1 jam lalu14.08
-0.26 (-1.81%)
| Penutupan Terdahulu | 14.34 |
| Buka | 14.25 |
| Jumlah Dagangan | 23,100 |
| Purata Dagangan (3B) | 36,550 |
| Modal Pasaran | 2,541,965,312 |
| Harga / Pendapatan (P/E TTM) | 5.31 |
| Harga / Pendapatan (P/E Ke hadapan) | 18.52 |
| Harga / Jualan (P/S) | 4.43 |
| Harga / Buku (P/B) | 1.93 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 5 Mar 2026 |
| Margin Keuntungan | 5.99% |
| Margin Operasi (TTM) | -4.99% |
| EPS Cair (TTM) | 0.200 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 6.40% |
| Pertumbuhan Pendapatan Suku Tahunan (YOY) | -84.70% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 11.64% |
| Nisbah Semasa (MRQ) | 2.83 |
| Aliran Tunai Operasi (OCF TTM) | -46.98 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -50.75 M |
| Pulangan Atas Aset (ROA TTM) | -2.14% |
| Pulangan Atas Ekuiti (ROE TTM) | 5.04% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Drug Manufacturers - Specialty & Generic (US) | Bercampur | Bercampur |
| Drug Manufacturers - Specialty & Generic (Global) | Bercampur | Bercampur | |
| Stok | HUTCHMED (China) Limited | Menurun | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 1.5 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | -1.5 |
| Osilator Teknikal | -2.5 |
| Purata | -1.13 |
|
HUTCHMED (China) Ltd is an biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures. |
|
| Sektor | Healthcare |
| Industri | Drug Manufacturers - Specialty & Generic |
| Gaya Pelaburan | Mid Growth |
| % Dimiliki oleh Orang Dalam | 0.12% |
| % Dimiliki oleh Institusi | 3.87% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Schroder Investment Management Group | 31 Dec 2025 | 2,279,541 |
| Allianz Asset Management Gmbh | 31 Dec 2025 | 908,804 |
| Aia Group Ltd | 31 Dec 2025 | 315,439 |
| M&G Plc | 31 Dec 2025 | 259,033 |
| Amundi | 31 Dec 2025 | 223,330 |
| Jane Street Group, Llc | 31 Dec 2025 | 107,995 |
| Ubs Group Ag | 31 Dec 2025 | 60,760 |
| Xy Capital Ltd | 31 Dec 2025 | 57,610 |
| Crossmark Global Holdings, Inc. | 31 Dec 2025 | 52,476 |
| Neos Investment Management Llc | 31 Dec 2025 | 49,573 |
| Dekabank Deutsche Girozentrale | 31 Dec 2025 | 41,362 |
| Julat 52 Minggu | ||
| Median | 20.00 (42.10%) | |
| Jumlah | 1 Beli | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| B of A Securities | 10 Mar 2026 | 20.00 (42.10%) | Beli | 13.89 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |